Avidity Biosciences (RNA) Form 4: 20,000 shares sold at $50.15

Avidity Biosciences (RNA) reported an insider transaction by its Chief Human Resources Officer.

Accepted by SEC EDGAR 10/17/2025 - 04:27 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Avidity Biosciences (RNA) reported an insider transaction by its Chief Human Resources Officer. On 10/15/2025, the officer exercised 20,000 stock options at an exercise price of $22.34 and sold 20,000 shares at a weighted-average price of $50.1529 under a Rule 10b5-1 trading plan adopted on April 11, 2025. Following the transactions, the officer directly held 97,130 shares. The filing notes a remaining 65,000 derivative securities (options). The sale price reflected multiple trades between $48.20 and $51.19.

Insider Trade Summary

Exercise and Sale: 20,000 shares ($556K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider McCarthy Teresa

Role Chief Human Resources Officer

Sold 20,000 shs ($1.00M)

Approx. gross sale proceeds $1.00M

Approx. exercise cost $447K

Approx. pre-tax spread $556K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	20,000	$0.00	$0.00
Exercise	Common Stock	20,000	$22.34	$447K
Sale	Common Stock	20,000	$50.1529	$1.00M

Holdings After Transaction: Stock Option (Right to Buy) — 65,000 contracts (Direct); Common Stock — 97,130 shares (Direct)

Footnotes (3)

1. F1. The exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on April 11, 2025.
2. F2. This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $48.20 to $51.19. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The shares subject to this option award are fully vested and exercisable as of the date hereof.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Avidity Biosciences (RNA) disclose in this Form 4?

An officer exercised 20,000 options at $22.34 and sold 20,000 shares at a weighted-average price of $50.1529 on 10/15/2025.

Was the RNA insider transaction under a Rule 10b5-1 plan?

Yes. The transactions were effected under a Rule 10b5-1 plan adopted on April 11, 2025.

How many Avidity Biosciences shares does the officer hold after the trades?

The officer directly holds 97,130 shares after the reported transactions.

What prices were the RNA shares sold at?

Sales occurred at a weighted-average of $50.1529, across multiple trades ranging from $48.20 to $51.19.

What derivative securities remain after the option exercise?

The filing shows 65,000 derivative securities (stock options) remaining.

What role does the reporting person hold at Avidity Biosciences?

The reporting person is the Chief Human Resources Officer.

What was the exercise price and size of the options exercised?

The officer exercised 20,000 options at an exercise price of $22.34.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McCarthy Teresa

(Last) (First) (Middle)

C/O AVIDITY BIOSCIENCES, INC.

3020 CALLAN RD.

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Avidity Biosciences, Inc. [ RNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Human Resources Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/15/2025		M(1)		20,000	A	$22.34	117,130	D
Common Stock	10/15/2025		S(1)		20,000	D	$50.1529(2)	97,130	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$22.34	10/15/2025		M(1)			20,000	(3)	02/01/2031	Common Stock	20,000	$0	65,000	D

Explanation of Responses:

1. The exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on April 11, 2025.

2. This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $48.20 to $51.19. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The shares subject to this option award are fully vested and exercisable as of the date hereof.

Remarks:

	/s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact	10/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.